When validated in independent studies, the observed results raise the possibility that LHR insLQ and GnRH 16Ser genotyping may provide additional prognostic information for premenopausal breast cancer patients in clinical practice and may result in tailored endocrine treatments for these patients. This evidence concerns the gene GNRH1 and breast carcinoma.